Matthew Roberge, MD
Family Medicine · Fremont, MINPI 1992997647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 252 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,426 and has fallen 95.8% since, to $60 in 2023.
Across 252 payments — averaging $12.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$457
- Novo Nordisk$436
- AstraZeneca$360
- Pfizer$321
- Takeda Pharmaceuticals U.S.A., Inc.$192
- Novartis$161
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,244100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $457 |
| Novo Nordisk | 48 | $436 |
| AstraZeneca | 13 | $360 |
| Pfizer | 33 | $321 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $192 |
| Novartis | 8 | $161 |
| Merck | 12 | $160 |
| Astellas Pharma US Inc | 9 | $153 |
| AbbVie(2 entities) | 9 | $146 |
| Boehringer Ingelheim | 9 | $135 |
| Otsuka America Pharmaceutical, Inc. | 8 | $116 |
| Teva Pharmaceuticals USA, Inc. | 7 | $91 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Johnson & Johnson | 5 | $51 |
| E.r. Squibb & Sons, L.L.C. | 4 | $49 |
| Amarin Pharma, Inc. | 3 | $46 |
| Amgen | 3 | $46 |
| UCB, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Regeneron Healthcare Solutions, Inc. | 2 | $23 |
| Medtronic | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Indivior Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$126
- BYDUREON$126
- FARXIGA$126
- BEVESPI AEROSPHERE$126
How this compares
$3,244 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $28,857 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,464 |
| JardianceEmpagliflozin | 11 | $9,666 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,474 |
| Atorvastatin Calcium | 122 | $2,045 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,232 |
| Omeprazole | 48 | $996 |
| Metoprolol Succinate | 50 | $936 |
| Aripiprazole | 12 | $827 |
| Tamsulosin Hcl | 40 | $776 |
| Lisinopril | 62 | $649 |
| ClopidogrelClopidogrel Bisulfate | 21 | $514 |
| Levothyroxine Sodium | 33 | $459 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $454 |
| Carvedilol | 23 | $447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $321 | $28,85729 claims |
| GSKTrelegy Ellipta | $457 | $10,46411 claims |
| Boehringer IngelheimJardiance | $135 | $9,66611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Fremont
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.